Broadfin Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Broadfin Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-658,929	Closed	-$15.6M	–	83
2014 Q3	$15.6M	Buy	658,929 +50,000	+8%	+$1.28M	1.64%	16
2014 Q2	$18.3M	Sell	608,929 -25,000	-4%	-$674K	1.78%	21
2014 Q1	$16.7M	Sell	633,929 -100,000	-14%	-$2.5M	1.62%	20
2013 Q4	$18.5M	Sell	733,929 -188,614	-20%	-$4.21M	2.43%	15
2013 Q3	$18.9M	Sell	922,543 -476,000	-34%	-$9.83M	3.35%	10
2013 Q2	$27.9M	Buy	+1,398,543	New	+$24.8M	5.45%	5

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Broadfin Capital's IPXL Position: Q4 2014 in Review

Broadfin Capital sold out of Impax Laboratories, Inc. (IPXL) in Q4 2014, closing a stake of 658,929 shares — an estimated $15.6M sold.

Broadfin Capital first reported a position in IPXL in Q2 2013 and held it in 6 quarters. The position peaked at $27.9M in Q2 2013. 178 funds tracked by Wall St. Rank hold IPXL as of Q4 2014.

Broadfin Capital reported no remaining Impax Laboratories, Inc. position as of Q4 2014 after selling out during the quarter.
Broadfin Capital sold 658,929 Impax Laboratories, Inc. shares in Q4 2014, an estimated $15.6M.
Broadfin Capital first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 6 quarters.
Broadfin Capital's Impax Laboratories, Inc. position peaked at $27.9M in Q2 2013.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2014.

Based on Broadfin Capital's 13F filing for Q4 2014, filed 17 Feb 2015.